Edition:
United States

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

85.90NOK
13 Dec 2017
Change (% chg)

kr4.90 (+6.05%)
Prev Close
kr81.00
Open
kr81.25
Day's High
kr87.00
Day's Low
kr81.05
Volume
596,405
Avg. Vol
230,517
52-wk High
kr113.00
52-wk Low
kr66.40

Latest Key Developments (Source: Significant Developments)

Nordic Nanovector Q3 comprehensive loss widens to NOK 85.9 mln​
Wednesday, 22 Nov 2017 01:03am EST 

Nov 22 (Reuters) - NORDIC NANOVECTOR ASA ::‍REVENUES FOR Q3 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)​.‍TOTAL OPERATING EXPENSES FOR Q3 WERE NOK 72.7 MILLION (NOK 50.4 MILLION)​.‍COMPREHENSIVE LOSS FOR Q3 AMOUNTED TO NOK 85.9 MILLION (LOSS OF NOK 61.3 MILLION)​.  Full Article

Nordic Nanovector says its share capital is NOK 9,808,880.40 divided into 49,044,402 shares
Wednesday, 30 Aug 2017 05:45am EDT 

Aug 30 (Reuters) - NORDIC NANOVECTOR ASA ::SAYS ITS SHARE CAPITAL IS NOK 9,808,880.40 DIVIDED INTO 49,044,402 SHARES, EACH WITH A NOMINAL OF NOK 0.20.  Full Article

Nordic Nanovector Q2 comprehensive widens to NOK 66.3 mln
Wednesday, 23 Aug 2017 01:00am EDT 

Aug 23 (Reuters) - NORDIC NANOVECTOR ASA :REVENUES FOR Q2 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION).COMPREHENSIVE LOSS FOR Q2 AMOUNTED TO NOK 66.3 MILLION (LOSS OF NOK 51.1 MILLION).  Full Article

Nordic Nanovector: Single dose Betalutin still shows promising efficacy and safety in recurrent iNHL
Wednesday, 14 Jun 2017 06:00am EDT 

June 14 (Reuters) - NORDIC NANOVECTOR ASA ::SINGLE DOSE BETALUTIN® CONTINUES TO SHOW PROMISING EFFICACY AND SAFETY IN RECURRENT INDOLENT NHL PATIENTS.SINGLE DOSE BETALUTIN® CONTINUES TO SHOW PROMISING EFFICACY AND SAFETY IN RECURRENT INDOLENT NHL PATIENTS.NORDIC NANOVECTOR - DATA CONTINUE TO SUPPORT COMPANY'S STRATEGY IN BETALUTIN'S DEVELOPMENT AND INTENT TO INITIATE OUR PIVOTAL PHASE 2 PARADIGME STUDY, IN SECOND HALF OF 2017.64% OVERALL RESPONSE RATE (ORR) AND 28% COMPLETE RESPONSES (CR) IN 47 EVALUABLE PATIENTS.  Full Article

Nordic Nanovector Q1 comprehensive loss NOK 55.8 million
Wednesday, 24 May 2017 01:00am EDT 

May 24 (Reuters) - NORDIC NANOVECTOR ASA :REVENUES IN Q1 2017 AMOUNTED TO NOK 0.078 MILLION (NOK 0.078 MILLION).COMPREHENSIVE LOSS FOR Q1 AMOUNTED TO NOK 55.8 MILLION (LOSS OF NOK 64.1 MILLION).TOTAL OPERATING EXPENSES FOR Q1 WERE NOK 65.8 MILLION (NOK 52.7 MILLION).CURRENT CASH RESOURCES ARE EXPECTED TO BE SUFFICIENT TO TAKE COMPANY BEYOND A FIRST REGULATORY SUBMISSION FOR BETALUTIN® IN FL IN FIRST HALF OF 2019.  Full Article

Nordic Nanovector Q4 operating loss widens to NOK 65.3 mln
Tuesday, 28 Feb 2017 01:28am EST 

Nordic Nanovector ASA : Q4 total revenue 0.1 million Norwegian crowns ($11,959.29) versus 0.1 million crowns year ago . Q4 operating loss 65.3 million crowns versus loss 33.3 million crowns year ago .Says current cash resources are now expected to be sufficient to take co beyond planned first regulatory submission for Betalutin in FL in H1 2019.  Full Article

Nordic Nanovector private placement oversubscribed
Wednesday, 7 Dec 2016 02:00am EST 

Nordic Nanovector ASA : Private placement successfully completed . Has raised 498.7 million Norwegian crowns ($59.3 million) in gross proceeds through private placement of 4.4 million new shares . Private placement was completed at subscription price of 114 crowns per share .Private placement was oversubscribed.  Full Article

Nordic Nanovector launches private placement of new shares
Tuesday, 6 Dec 2016 10:58am EST 

Nordic Nanovector ASA : Launches private placement of up to 4,374,244 new shares, representing about 10 pct of outstanding share capital of company . Subscription price, number of shares to be issued in offering will be determined via accelerated bookbuilding process .Will use net proceeds to fund, among others, Phase 2 combination study of Betalutin and Rituximab CD20, Phase 1 study and GMP manufacturing for 177Lu-conjugated chimeric antibody.  Full Article

Wilex subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration
Wednesday, 26 Oct 2016 01:00am EDT 

Wilex AG : Subsidiary Heidelberg Pharma and Nordic Nanovector enter into collaboration to develop novel antibody drug conjugates (ADC) .Collaboration aims at developing novel antibody drug conjugates (ADCS) to treat leukemias.  Full Article

Nordic Nanovector and Heidelberg Pharma enter collaboration
Wednesday, 26 Oct 2016 01:00am EDT 

Nordic Nanovector ASA :Says the company and Heidelberg Pharma, subsidiary of biopharmaceutical company WILEX AG, enter collaboration to develop novel antibody-drug conjugates (ADCS) targeting leukaemias.  Full Article

BRIEF-Nordic Nanovector presents updated results

* BETALUTIN® SHOWS STRONG CLINICAL PROFILE IN RELAPSED/REFRACTORY INDOLENT NHL AND FOLLICULAR LYMPHOMA